- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00085384
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients With Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2b and to see how well it works in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Determine the optimum biologic dose of PEG-interferon alfa-2b in patients with platinum-resistant ovarian epithelial, peritoneal, or fallopian tube cancer.
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 3 different treatment arms.
- Arm I: Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
- Arm II: Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
- Arm III: Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for at least 28 days after study treatment.
PROJECTED ACCRUAL: A maximum of 75 patients will be accrued for this study within 19 months.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- M D Anderson Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Women with platinum-resistant epithelial ovarian, fallopian tube or peritoneal cancer whose tumor test positive for IL-8 (>31.0 pg/ml), bFGF >7.0 pg/ml), or VEGF (>700 pg/ml). Resistance is defined as:
- Progression of disease during platinum chemotherapy, or
- Progression of disease within 6 months of completing platinum chemotherapy
- Failure to achieve a complete response, with persistent macroscopic disease, after 6 cycles of chemotherapy, if the last two cycles had no measurable change in disease status
- Patients with a known hypersensitivity to platinum compounds who have failed a desensitization regimen, or who are not good candidates for desensitization are eligible.
- Patients are limited to 4 prior chemotherapy regimens (all platinum and taxane regimens to be counted as one).
- Patients must have measurable disease.
- Women of any racial and ethnic group.
- Zubrod performance status < 2.
- Expected survival of > 12 weeks.
- Patients must have adequate hepatic, renal, and bone marrow function, defined as serum creatinine < 2 mg/dl (estimated creatinine clearance 50 ml/min); total bilirubin < 2.0 X the upper limit of normal (ULN); alanine aminotransferase (ALT) < 2X ULN; fasting triglycerides < 800 mg/dL; white blood count (WBC) > 3,000/mm3 ; absolute neutrophil count (ANC) > 1,500/mm3; platelets > 100,000/mm3, hemoglobin > 9 g/dl.
- At least three weeks must have elapsed from completion of chemotherapy.
- Patient agrees not to use complementary alternative medications (e.g., shark cartilage).
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the hospital. The only approved consent is appended to this protocol.
Exclusion Criteria:
- Patients with borderline, low grade or low malignant potential tumors are not eligible.
- Patients who are pregnant or lactating.
- Concurrent chemotherapy, radiation therapy or surgery.
- Concurrent, uncontrolled, medical or psychiatric disorders.
- Patients with a known hypersensitivity to interferon.
- Patients with severe cardiovascular disease (i.e. arrhythmias requiring chronic treatment or congestive heart failure) (NYHA classification III or IV).
- Patients who have had interferon within the last 6 months.
- Patients with overt psychosis or mental disability or otherwise incompetent to give informed consent.
- Patients with a known autoimmune disorder.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: PEG-interferon alfa-2b
Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
|
Starting dose 1.0 mg/kg/week given subcutaneously
Andre navn:
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.5 mg/kg/week given subcutaneously EG-Intron
Andre navn:
|
Eksperimentell: Arm II
Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
|
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.25 mg/kg/week given subcutaneously
Andre navn:
|
Eksperimentell: Arm III
Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
|
Starting dose 1.0 mg/kg/week given subcutaneously
Andre navn:
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.5 mg/kg/week given subcutaneously EG-Intron
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Optimal Biologic Dose at 8 weeks
Tidsramme: 8 weeks
|
Optimum biologic dose of PEG Intron in patients with platinum-resistant ovarian, fallopian tube or peritoneal cancer whose tumors test positive for IL-8, BFGF, or VEGF.
|
8 weeks
|
Tumor Response
Tidsramme: Every 2 -3 cycles (8 - 12 weeks)
|
Each patient tumor response scored as either complete/partial response (CR/PR), stable disease (SD), or failure (F) at 8 weeks after initial treatment.
|
Every 2 -3 cycles (8 - 12 weeks)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Judith K. Wolf, MD, M.D. Anderson Cancer Center
- Studiestol: Pedro T. Ramirez, MD, M.D. Anderson Cancer Center
- Studiestol: Diane C. Bodurka, MD, M.D. Anderson Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Genitale neoplasmer, kvinnelige
- Adnexal sykdommer
- Eggledersykdommer
- Egglederneoplasmer
- Fysiologiske effekter av legemidler
- Anti-infeksjonsmidler
- Antivirale midler
- Antineoplastiske midler
- Immunologiske faktorer
- Interferoner
- Interferon-alfa
- Interferon alfa-2
- Peginterferon alfa-2b
Andre studie-ID-numre
- ID02-115
- P30CA016672 (U.S. NIH-stipend/kontrakt)
- P50CA083639 (U.S. NIH-stipend/kontrakt)
- MDA-ID-02115 (Annen identifikator: UT MD Anderson Cancer Center)
- CDR0000368964 (Registeridentifikator: NCI PDQ)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Eggstokkreft
-
Children's Oncology GroupNational Cancer Institute (NCI)RekrutteringOndartet kimcellesvulst | Kimcelletumor | Ekstrakraniell kimcellesvulst i barndommen | Ekstragonadal embryonal karsinom | Ondartet ovarieteratom | Stadium I Ovarial Choriocarcinoma | Fase I Ovarial Embryonal Carcinoma AJCC v6 og v7 | Stage I Ovarian Teratoma AJCC v6 og v7 | Stage I Eggstokkeplommesekktumor... og andre forholdForente stater, Canada, Japan, Australia, Puerto Rico, New Zealand, Saudi-Arabia, Storbritannia, India
-
National Cancer Institute (NCI)AvsluttetEgglederkreft | Tynntarms lymfom | Tilbakevendende kreft i bukspyttkjertelen | Stadium III Bukspyttkjertelkreft | Stadium IV Bukspyttkjertelkreft | Stadium IV Ovarieepitelkreft | Stadium IV Ovariekimcelletumor | Primær peritoneal kreft | Stadium IIIA Ikke-småcellet lungekreft | Stadium IIIB Ikke-småcellet... og andre forholdForente stater
Kliniske studier på PEG-interferon alfa-2b
-
Brooke Army Medical CenterT.R.U.E. Research FoundationFullført
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendePrimær myelofibrose | Sekundær myelofibroseForente stater
-
Northwestern UniversityNational Cancer Institute (NCI)Avsluttet
-
Shanghai General Hospital, Shanghai Jiao Tong University...FullførtTilbakefall | Hematologiske neoplasmerKina
-
Merck Sharp & Dohme LLCAvsluttet
-
M.D. Anderson Cancer CenterNovartisFullførtLeukemi, Myeloid, KroniskForente stater
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedFullført
-
NovartisHuman Genome Sciences Inc.FullførtKronisk hepatitt CTaiwan, Tyskland, Hellas, Italia, Spania, Storbritannia, Frankrike, Canada, Australia, India, Polen, Thailand
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)FullførtMelanom (hud)Forente stater
-
Emory UniversityCURE Childhood Cancer, Inc.FullførtJuvenile pilocytiske astrocytomer | Optic Pathway GliomasForente stater